

## Expiry of Voluntary Escrow Conditions

Nova Eye Medical Limited (ASX EYE) advises that in accordance with Listing Rule 3.10A, 1,736,653 fully paid ordinary shares that are currently subject to voluntary escrow, will cease to be escrowed on the 24 August 2022

This release dated 12 August 2022 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

### Company

Tom Spurling  
Managing Director  
+61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

### Media

Kate Hunt  
Head of Marketing  
+61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

### Investors

Mark Flynn  
Investor Relations  
+61 416 068 733  
[mflynn@nova-eye.com](mailto:mflynn@nova-eye.com)

### ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:  
[www.nova-eye.com](http://www.nova-eye.com)